HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ICLR
ICON Public Limited Company
There isn't enough reported data to score ICLR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ICLR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Stable |
ICLR's revenue and cash flow are currently healthy, and its profitability and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ICLR PE Valuation
ICLR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ICLR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ICLR's earnings, revenue and profitability to hold roughly steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
ICLR has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus ICLR down 70%.
ICLR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +288% |
| Q4 2025 | $2.90 | -70% |
| Q3 2025 | $7.39 | -18% |
| Q2 2025 | $9.72 | +13% |
| Q1 2025 | $9.18 | +11% |
| Q4 2024 | $9.53 | +29% |
| Q3 2024 | $8.99 | +45% |
| Q2 2024 | $8.60 | +39% |
| Q1 2024 | $8.24 | +33% |
ICLR earned $2.90 per share over the past year, down 70% from the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ICLR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ICLR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | -0.9% |
| Q2 2026 | $2.1B | +2.3% |
| Q1 2026 | $2B | +1.6% |
| Q4 2025 | $8.3B | +304% |
| Q3 2025 | $2B | +0.6% |
| Q2 2025 | $2B | -4.8% |
| Q1 2025 | $2B | -4.3% |
| Q4 2024 | $2B | -1.2% |
ICLR's revenue has picked up after three years of holding roughly level: $2B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +5.6 points |
| Q2 2026 | 6.7% | -3.7 points |
| Q1 2026 | 8.5% | -2.4 points |
| Q4 2025 | 5.4% | -9.2 points |
| Q3 2025 | 4.2% | -9.8 points |
| Q2 2025 | 10% | -0.5 points |
| Q1 2025 | 11% | -2.7 points |
| Q4 2024 | 15% | +1.7 points |
ICLR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ICLR on cash flow, with more consistent year-over-year improvement.
ICLR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $307.1M | -8% |
| Q2 2026 | $238.8M | +110% |
| Q1 2026 | $136.2M | -43% |
| Q4 2025 | $862M | +211% |
| Q3 2025 | $333.9M | -7.1% |
| Q2 2025 | $113.9M | -38% |
| Q1 2025 | $239.3M | -20% |
| Q4 2024 | $277M | -28% |
ICLR generated $1.5B in free cash flow over the past year, up 60% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ICLR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ICLR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +32.7K shares |
| 1 year | -0.9% | -678K shares |
| 3 years | -6.7% | -5.6M shares |
| 5 years | -4.2% | -3.4M shares |
| Available history | +42% | +23.1M shares |
ICLR has 77M diluted shares, down 0.9% from a year ago, with $1.1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $750M |
| Q3 2025 | $250M |
| Q2 2025 | $250M |
| Q1 2025 | $250M |
| Q4 2024 | $400M |
ICLR spent $1.1B buying back its own shares over the past year, about the same as the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ICLR on leverage, with a lower net debt burden relative to earnings.
ICLR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 1.7x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.9x | Healthy |
ICLR's net debt is about 2.7 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ICLR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 79.3 | Neutral |
ICLR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ICLR PE vs Healthcare Sector
| Metric | ICLR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ICLR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ICLR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.8 | 9.1% above |
| 20 week MA | $173.9 | 15% above |
| 50 week MA | $152.9 | 31% above |
| 100 week MA | $161.8 | 24% above |
| 200 week MA | $213.5 | 6.1% below |
ICLR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ICLR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $171.9 | $192.5 | +12% |
| 2021 | $192.5 | $307.9 | +60% |
| 2022 | $307.9 | $194.9 | -37% |
| 2023 | $194.9 | $283.1 | +45% |
| 2024 | $283.1 | $212.3 | -25% |
| 2025 | $212.3 | $182.8 | -14% |
| 2026 YTD | $182.8 | $200.5 | +9.7% |
ICLR has the edge over HIMS on returns for 2026, with the stronger performance.